



Canon Showcasing Carotid Stenotic Scan (CSS) At NPE The World's Largest Plastics Tradeshow

Canon NPE

VANCOUVER, BC, CANADA, May 7, 2018 /EINPresswire.com/ -- VANCOUVER, BC / May 7th, 2018 / CVR Medical Corp. (TSX.V: CVM.V)(FRANKFURT: B3BN) (OTCQB: CRRVF) ("CVR Medical" or "CVR") is pleased to announce that Canon Virginia, Inc. (CVI) will be showcasing our Carotid Stenotic Scan (CSS) at NPE 2018: The Plastics Show, the world's leading plastic tradeshow. Canon Virginia, Inc. (CVI), a wholly owned subsidiary of Canon U.S.A., Inc., provides custom manufacturing solutions, including mold making, injection molding, medical contract manufacturing and automated assembly capabilities. NPE Participants includes buying teams from over 100 countries and more than 20,000 companies comprising the entire global plastics supply chain. NPE draws over 2,000 exhibiting companies, 65,000 manufacturing representatives from every segment of the plastic industry and its vertical markets including, medical devices and supplies, automotive, building and construction, packaging and consumer products.

CVR COO Tony Robinson states, "We are honored to have our CSS Device showcased at NPE and show off the results from what has been an incredible partnership. Working with CVI to create the best possible design, and have it manufactured with a streamlined supply chain, has made it possible for us to aim for our highest goals. They have set a new industry quality standard, and we're proud to reflect that with our device."

"This year's booth at NPE will feature some of Canon's latest manufacturing technologies. We are proud CVR has partnered with us to showcase the CSS Device," said Toru Nishizawa, President and CEO, Canon Virginia Inc. "The CSS Device demonstrates both companies' commitment in making an impact on the medical device industry. Come by and see the device in booth W223."

For additional information on the organization, leadership, and current news please visit the company website www.CVRMed.com

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

ON BEHALF OF THE BOARD:

(signed) "Peter Bakema"
CEO, President & Director

For further information contact:
Peter Bakema, CEO, President and Director

Telephone: (734) 718-5115

Email: info@cvrmed.com

or

Marc S. Lubow

Vice President, Capital Markets, Investor Relations

Telephone: (904) 923 -4037

marc.lubow@cvrmed.com

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

Peter Bakema

CVR Medical Corp.

604-669-0780

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.